Charles-Schoeman et al. revealed that RA patients treated with JAKi experienced a significant reduction in the inflammatory marker CRP, an elevation of HDL levels, and a concurrent improvement in HDL function [39]. Here, CRP is linked to rheumatoid arthritis.